Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Share:
Related GALE
15 Stocks Moving In Tuesday's Pre-Market Session
Mid-Afternoon Market Update: Dow Surges 250 Points; Juno Therapeutics Shares Tumble

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Latest Ratings for GALE

DateFirmActionFromTo
Jun 2016Raymond JamesDowngradesOutperformMarket Perform
Mar 2016Roth CapitalMaintainsBuy
Dec 2015Cantor FitzgeraldUpgradesSellHold

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

View Comments and Join the Discussion!